Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-08-27 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于公司2024年中期利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2024 interim profit distribution plan, including details on dividend payments and the approval process by the board and supervisory committee. It contains no full financial statements or comprehensive financial analysis but focuses on the dividend distribution decision and related approvals. The document length is short (1818 characters) and it is clearly an announcement of a dividend plan rather than a full financial report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV).
2024-08-27 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司部分募投项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a verification opinion from CITIC Securities regarding the delay of certain fundraising investment projects by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes detailed information about the fundraising amount, usage progress, reasons for delay, and approvals by the board and supervisory committee. The document references regulatory guidelines and confirms compliance but does not contain full financial statements or comprehensive financial performance data. It is a specialized report related to fundraising project progress and compliance verification, not a full annual or interim report, earnings release, or capital update. Given the focus on fundraising project delay verification and compliance, this fits best under Capital/Financing Update (CAP). The document length is 2645 characters, which is short but contains substantive content about fundraising project status and regulatory compliance, not just an announcement or certification. Therefore, the classification is CAP with high confidence.
2024-08-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the approval of the 2024 semi-annual report and its summary, a special report on the use of raised funds, a mid-year profit distribution plan, and the postponement of some fundraising projects. The document does not contain the actual semi-annual report or financial statements but rather the Supervisory Board's approval and confirmation that these reports comply with relevant regulations. It also references that the full reports are disclosed elsewhere (on cninfo.com.cn). The document length is short (1882 characters) and serves as an official meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of supervisory board resolutions and approvals related to interim reports and fundraising usage, not the interim report itself.
2024-08-27 Chinese
关于2024年半年度募集资金存放和使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年半年度募集资金存放和使用情况专项报告" which translates to "2024 Semi-Annual Special Report on the Deposit and Use of Raised Funds." It details the amount of funds raised, their usage, balance, management, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial figures related to fundraising and usage for the half-year period ending June 30, 2024. The content is focused on the management and use of capital raised through share issuance, not a general financial performance report or earnings release. It is a specialized report on capital raising and fund usage, which aligns with the category "Capital/Financing Update (CAP)." The document length is over 6,000 characters and contains substantive financial data about fundraising and usage, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2024-08-27 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 18th meeting of the third board of directors of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes details about the board meeting date, attendance, and voting results on several agenda items such as approval of the 2024 semi-annual report and its summary, a special report on the use of raised funds, the 2024 interim profit distribution plan, and the postponement of some investment projects. The document references the actual reports being disclosed on an external website (cninfo.com.cn) but does not contain the full reports or detailed financial statements itself. The document is primarily a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (2137 characters), and it is not the report itself but an announcement of board decisions related to reports and other corporate matters.
2024-08-27 Chinese
2024年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2024. It includes specific financial figures such as beginning balances, cumulative amounts, interest, repayments, and ending balances for the half-year period. The presence of half-year period data and detailed financial figures indicates this is a substantive financial report for a period shorter than a full fiscal year. The document does not appear to be an announcement or a certification but contains actual financial data and analysis related to the company's financial dealings with related parties. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.